undamentalytics Newsletter
Sign in

Argenx SE (ARGX) stock

Add to watchlist

Add holding +

NASDAQ: ARGX Nasdaq Biotechnology

B+ Fundamentals grade

Argenx SE is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$390

Valuation models combined (3)

Base case. Range ~$350–$450. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Argenx SE valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds259 adding, 208 cuttingOf 62 active managers that changed their stake, 27 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Argenx SE files

Where Argenx SE stands after its latest Filing

Revenue for the twelve months was $4.15bn, up 89.9% on a year earlier, faster than the 83.6% growth a quarter earlier. Free-cash-flow margin rose to 16.4% from -122.8% a year earlier. Operating margin widened to 25.4% from -70.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B+. It passes 3 of our 3 financial-health checks. Our valuation models combined value is $387 a share, against a share price of $893.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Argenx SE's trailing-twelve-month revenue grew 89.9% year on year, with a free-cash-flow margin of 16.4%. Where it stands out: net margin of 31.1% ranks 17 of 180 biotechnology companies we cover. Where it lags: days sales outstanding of 145 days ranks 82 of 100 biotechnology companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 128% in the quarter to 2026-09-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 89.9% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 6.3 points higher than a quarter earlier.
  • High operating margin. 25.4% of revenue is left as operating profit, against a median of -189.4% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 26.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $3.5bn.

Things to watch

  • Weak cash conversion. Free cash flow was 53% of net income over the last 12 months.
  • Below peers: days sales outstanding. Days sales outstanding of 145 days ranks 82 of 100 biotechnology companies we cover (median 75 days).
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 12.1% over 90 days.

Latest results

Earnings per share
$7.80 against an average estimate of -$27.83: beat by 128.0%
Next report
October 22, 2026; average EPS estimate $7.32

Argenx SE's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.0%
  • 1 week+0.6%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.2B
Operating margin
25.4%
Net margin
31.1%
EPS (TTM, diluted)
$19.57

Growth

Revenue growth
+89.9%
Change in growth rate
+6.3 pts
Share count change
+1.3%

Cash

Free cash flow (TTM)
$679M
FCF margin
16.4%
Stock pay % of revenue
6.0%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for ARGX from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Argenx SE valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Argenx SE as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$350 ~$240–$430 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$400 ~$380–$770 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$4.8 ~$1.1–$11 Left out: out of range vs price (0.01x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: earnings are positive: price-to-earnings is the better measure
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$450 ~$380–$530 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$390 ~$350–$450 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Argenx SE with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $28.27 +45% $6.4bn +50%
Next $33.31 +18% $7.8bn +22%

Next year's EPS estimate has moved −12.1% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.3% on 90 days ago. In the last 30 days, 1 analyst raised Argenx SE's forecast and 1 cut it.

Consensus EPS forecast Argenx SE, last 90 days
$10.00 $20.00 $30.00 $40.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $27.91 Current fiscal year, 60 days ago: $27.11 Current fiscal year, 30 days ago: $18.36 Current fiscal year, 7 days ago: $18.68 Current fiscal year, Now: $28.27 $28.27 Next fiscal year, 90 days ago: $37.89 Next fiscal year, 60 days ago: $39.34 Next fiscal year, 30 days ago: $34.72 Next fiscal year, 7 days ago: $35.59 Next fiscal year, Now: $33.31 $33.31

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $27.91$37.89
60 days ago $27.11$39.34
30 days ago $18.36$34.72
7 days ago $18.68$35.59
Now $28.27$33.31

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$27.83 $7.80 +128.0%
Jun 2026 $6.19 $7.32 +18.2%
Mar 2026 $4.92 $5.52 +12.1%
Dec 2025 $6.11 $8.02 +31.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

23 analysts, Nov 2026
Buy2087%
Hold313%
Sell00%

Monthly trend

  1. Nov 2026713323
  2. Oct 2026715325
  3. Sep 2026715325

Counts of recommendations published by analysts covering Argenx SE, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.1%
of tradable shares
Days to cover
3.31
at average volume
Short interest, 1 month
+3%
to October 15, 2026
Held by institutions
46%
of shares
Held by insiders
0.0%
of shares
Employees
1,863
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Argenx SE in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Argenx SE
$0 $2B $4B $6B FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue (TTM), FY18 Q4: $21.5M Revenue (TTM), FY19 Q4: $78.5M Revenue (TTM), FY20 Q4: $41.2M Revenue (TTM), FY21 Q4: $497.3M Revenue (TTM), FY22 Q4: $400.7M Revenue (TTM), FY23 Q4: $1.2B Revenue (TTM), FY24 Q4: $2.2B Revenue (TTM), FY25 Q4: $4.2B $4.2B

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY18 Q4 $21.5M
FY19 Q4 $78.5M
FY20 Q4 $41.2M
FY21 Q4 $497.3M
FY22 Q4 $400.7M
FY23 Q4 $1.2B
FY24 Q4 $2.2B
FY25 Q4 $4.2B
Revenue growth, TTM YoY Argenx SE
-500% 0% 500% 1000% 1500% FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue growth, TTM YoY, FY19 Q4: 265.2% Revenue growth, TTM YoY, FY20 Q4: -47.4% Revenue growth, TTM YoY, FY21 Q4: 1105.7% Revenue growth, TTM YoY, FY22 Q4: -19.4% Revenue growth, TTM YoY, FY23 Q4: 197.2% Revenue growth, TTM YoY, FY24 Q4: 83.6% Revenue growth, TTM YoY, FY25 Q4: 89.9% 89.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY19 Q4 265.2%
FY20 Q4 -47.4%
FY21 Q4 1105.7%
FY22 Q4 -19.4%
FY23 Q4 197.2%
FY24 Q4 83.6%
FY25 Q4 89.9%
Operating margin (TTM) Argenx SE
-1500% -1000% -500% 0% 500% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Operating margin (TTM), FY18 Q4: -381.0% Operating margin (TTM), FY19 Q4: -253.5% Operating margin (TTM), FY20 Q4: -1158.1% Operating margin (TTM), FY21 Q4: -70.1% Operating margin (TTM), FY22 Q4: -179.8% Operating margin (TTM), FY23 Q4: -35.7% Operating margin (TTM), FY24 Q4: -1.0% Operating margin (TTM), FY25 Q4: 25.4% 25.4%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY18 Q4 -381.0%
FY19 Q4 -253.5%
FY20 Q4 -1158.1%
FY21 Q4 -70.1%
FY22 Q4 -179.8%
FY23 Q4 -35.7%
FY24 Q4 -1.0%
FY25 Q4 25.4%
FCF margin (TTM) Argenx SE
-1000% -500% 0% 500% FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY19 Q4: 191.0% FCF margin (TTM), FY20 Q4: -968.7% FCF margin (TTM), FY21 Q4: -122.8% FCF margin (TTM), FY22 Q4: -215.5% FCF margin (TTM), FY23 Q4: -35.4% FCF margin (TTM), FY24 Q4: -3.9% FCF margin (TTM), FY25 Q4: 16.4% 16.4%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY19 Q4 191.0%
FY20 Q4 -968.7%
FY21 Q4 -122.8%
FY22 Q4 -215.5%
FY23 Q4 -35.4%
FY24 Q4 -3.9%
FY25 Q4 16.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Argenx SE took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $4.2B
  2. Other income $238M · 5.7%
  3. Cost of revenue $451M · 10.9%
  4. Gross profit $3.7B · 89.1%
  5. Research and development $1.4B · 32.9%
  6. Other operating costs $1.3B · 30.9%
  7. Operating income $1.1B · 25.4%
  8. Net income $1.3B · 31.1%

Shares of revenue. Source: Argenx SE's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 8 16 41 21 78 41 497 401 1,191 2,186 4,151
Gross profit — — — — — — — 371 1,073 1,959 3,701
Operating income −17 −24 −26 −82 −199 −478 −349 −720 −425 −22 1,054
Net income −17 −24 −32 −67 −181 −608 −408 −710 −295 833 1,292
Diluted EPS — — — — −$4.69 −$13.40 −$7.99 −$13.05 −$5.16 $12.78 $19.57
Growth (year on year)
Revenue — +114.2% +152.6% −47.8% +265.2% −47.4% +>999% −19.4% +197.2% +83.6% +89.9%
Net income — — — — — — — — — — +55.1%
Diluted EPS — — — — — — — — — — +53.1%
Margins
Gross margin — — — — — — — 92.7% 90.1% 89.6% 89.1%
Operating margin −227.7% −145.6% −63.0% −381.0% −253.5% <−999% −70.1% −179.8% −35.7% −1.0% 25.4%
Net margin −223.4% −145.3% −77.1% −310.2% −230.9% <−999% −82.1% −177.1% −24.8% 38.1% 31.1%
Free-cash-flow margin −206.8% 66.3% −101.3% — 191.0% −968.7% −122.8% −215.5% −35.4% −3.9% 16.4%
Cash flow
Cash from operations −15 12 −41 — 152 −398 −607 −863 −420 −83 685
Capital spending 0 1 0 — 2 1 4 1 1 2 6
Free cash flow −16 11 −42 — 150 −400 −610 −864 −421 −85 679
Stock-based pay 3 3 5 — 44 97 179 157 233 235 248
Free cash flow after stock pay −18 8 −47 — 106 −496 −790 −1,021 −654 −320 431
Balance sheet
Cash 39 95 229 322 372 1,217 1,335 801 2,049 1,500 3,491
Total debt — — — 0 0 0 0 0 7 — 0
Net debt (negative = net cash) −39 −95 −229 −322 −372 −1,217 −1,335 −801 −2,042 −1,500 −3,491
Diluted shares 16m 19m 25m 33m 39m 45m 51m 54m 57m 65m 66m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Older annual columns retain the reporting standard and currency used in those filings, translated separately to USD. Current filings replace overlapping periods. Reporting changes can affect comparability; older bases are not used to fill current valuation inputs.

Financial health

3 of 3 checks passed · December 31, 2025
What it owns · $8.7bn
Short-term assets $6.9bnLonger-term assets $1.8bn
What it owes, and who funded it · $8.7bn
Short-term liabilities $1.3bnLonger-term liabilities $39mShareholders' equity $7.3bn
  • Short-term assets cover short-term liabilities $6.9bn of assets due within a year against $1.3bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $6.9bn short-term assets against $39m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $1.1bn against $3m of interest.

From Argenx SE's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.3%
year over year
R&D spending
32.9%
of revenue
Days sales outstanding
145 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ARGX NBIX BMRN BNTX UTHR INCY Median
Revenue, last 12 months $4.2bn $3.7bn $3.4bn $3.2bn $3.2bn $6.0bn $56m
Revenue growth, last 12 months 89.9% 38.0% 11.2% 9.0% 2.5% 24.9% 12.6%
Revenue growth, 3-year average — 27.5% 15.1% — 14.3% 18.5% 13.7%
Revenue growth, latest quarter — 41.2% 19.9% — −1.9% 14.0% 10.2%
Gross margin 89.1% 98.2% 76.1% 77.6% 86.1% 92.7% 82.9%
Operating margin 25.4% 24.0% 4.4% −49.0% 44.4% 10.4% −189.4%
Operating margin, 3-year average — 23.4% 13.3% −22.6% 46.6% 13.3% −363.5%
Net margin 31.1% 19.0% 2.1% −39.6% 41.6% 6.7% −169.8%
Cash from operations / revenue 16.5% 28.8% 25.2% 15.9% 53.4% 12.4% −168.0%
Free-cash-flow margin 16.4% 28.1% 21.7% 9.8% 34.6% 10.8% −162.4%
Free-cash-flow margin, 3-year average — 23.3% 17.8% −37.0% 34.3% 11.7% −310.0%
Stock pay / revenue 6.0% 6.4% 6.3% 3.7% 4.9% 4.4% 20.0%
Change in share count 1.3% 1.9% 1.0% 0.5% −3.1% 2.9% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 89.9% 12.6% 43 of 172
Change in growth rate Growth +6.3pp -0.1pp 51 of 172
Gross margin Profitability 89.1% 82.4% 24 of 75
Operating margin Profitability 25.4% -189.4% 20 of 175
Net margin Profitability 31.1% -157.3% 17 of 180
Free-cash-flow margin Cash generation 16.4% -145.4% 28 of 176
Stock pay as % of revenue Cash generation 6.0% 19.2% 40 of 179
Change in share count Balance sheet 1.3% 7.9% 41 of 156
Days sales outstanding Balance sheet 145 days 75 days 82 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$26.1B
Institutions reporting
505
Shares held vs prior quarter
▼ 1.9%
Positions opened / closed
78 / 47

Top buyers and sellers, Q2 2026: 259 institutions bought and 208 sold ; the biggest buyer was FMR LLC (+240K shares) and the biggest seller Price T Rowe Associates Inc (−697K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $4.9B 5.2M 18.6% ▲ 4.8%
Price T Rowe Associates Inc $2.5B 2.7M 9.5% ▼ 20.6%
Jupiter Topco LLC $2.3B 2.5M 8.8% —
Capital World Investors $2B 2.2M 7.8% ▼ 2.5%
Artisan Partners Limited Partnership $1.4B 1.5M 5.4% ▲ 2.8%
Avoro Capital Advisors LLC $928M 1.0M 3.6% 0.0%
Wellington Management Group LLP $863M 931K 3.3% ▼ 8.9%
Blackrock, Inc. $721M 777K 2.8% ▼ 3.8%
RTW Investments, LP $658M 709K 2.5% 0.0%
Morgan Stanley $597M 643K 2.3% ▲ 14.7%
Invesco Ltd. $412M 444K 1.6% ▼ 25.3%
Bank Of America Corp $371M 400K 1.4% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Argenx SE's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Argenx SE disclosed in the last 12 months; 1 earlier trade on record.

  • Daniel S. Goldman(D-NY 10):Sale (full), $1,001 - $15,000, traded July 10, 2023, filed August 13, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Argenx SE was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Argenx SE in brief

What does Argenx SE do?
Argenx SE is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Argenx SE's stock ticker?
Argenx SE trades under the ticker ARGX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Argenx SE's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Argenx SE reported revenue of $4.2B, 89.9% higher than a year earlier, according to its SEC filings.
What is Argenx SE's free cash flow?
Argenx SE's free-cash-flow margin is 16.4% of revenue over the trailing twelve months, ranking 28 of the 176 biotechnology companies we cover.
Who are Argenx SE's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Price T Rowe Associates Inc and Jupiter Topco LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Argenx SE's competitors?
In our Biotechnology peer group, the companies closest to Argenx SE are Neurocrine Biosciences Inc, Biomarin Pharmaceutical Inc, Biontech SE, United Therapeutics Corp and Incyte. The side-by-side comparison below sets their revenue, margins and growth against Argenx SE's.